IR501: Will begin by the end of July enrollment in a 90-patient Phase II trial

The Immune Response Corp. (IMNR), Carlsbad, Calif. Product: IR501, three synthetic peptides identified in joints, to immunize against T cells involved in rheumatoid arthritis Indication: Rheumatoid ar...